Meta Information
ID:dasatinib
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/class/cyp3a4-strong-inhibitors
Target name:
Strong CYP3A4 Inhibitors
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Strong CYP3A4 inhibitors block the primary enzyme that breaks down dasatinib, causing its levels to rise to potentially toxic concentrations and increasing the risk of severe side effects.
Actionable advice:
Avoid this combination; if medically necessary, a significant dose reduction of dasatinib is required under strict medical supervision.
Target id:
/dietary/grapefruit-pomelo
Target name:
Grapefruit or Grapefruit Juice
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Grapefruit contains compounds that strongly inhibit the CYP3A4 enzyme in the gut, which can dramatically increase dasatinib absorption and blood levels, raising toxicity risk.
Actionable advice:
Avoid consuming grapefruit, its juice, or Seville oranges entirely while taking dasatinib.
Target id:
/class/broad-spectrum-inducers
Target name:
Strong CYP3A4 Inducers
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Description:
These agents speed up the enzyme that metabolizes dasatinib, causing it to be cleared from the body too quickly, which can render the treatment ineffective.
Actionable advice:
Avoid this combination; if medically necessary, a significant dose increase of dasatinib may be required under strict medical supervision.
Target id:
/intervention/saint-johns-wort
Target name:
Saint John's Wort
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Description:
St. John's Wort is a potent inducer of the CYP3A4 enzyme, which can dramatically lower dasatinib blood levels and compromise its therapeutic effect.
Actionable advice:
Avoid St. John's Wort completely while taking dasatinib.
Target id:
/class/proton-pump-inhibitors
Target name:
Proton Pump Inhibitors (PPIs)
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Description:
PPIs profoundly suppress stomach acid for an extended period. Dasatinib requires an acidic environment to dissolve and be absorbed, so PPIs can severely reduce its effectiveness.
Actionable advice:
Avoid using PPIs concurrently. Consider alternatives like H2 blockers or antacids with appropriate timing.
Target id:
/class/qt-prolonging-agents
Target name:
QT-Prolonging Medications
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Dasatinib can prolong the QT interval of the heart; combining it with other drugs that do the same increases the risk of a serious and potentially fatal heart rhythm disorder.
Actionable advice:
Avoid co-administration with other QT-prolonging drugs; requires close cardiac monitoring if unavoidable.
Target id:
/class/anticoagulants-antiplatelets
Target name:
Anticoagulants and Antiplatelets
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Dasatinib can impair platelet function. When combined with other blood-thinning medications (e.g., warfarin, apixaban, clopidogrel, aspirin), it significantly increases the risk of serious bleeding.
Actionable advice:
Use this combination only with extreme caution and under close medical supervision, monitoring for any signs of bleeding.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Based on its mechanism and animal studies, dasatinib is expected to cause harm to a developing fetus.
Actionable advice:
Dasatinib is contraindicated in pregnancy; effective contraception must be used during treatment and for 30 days after the final dose.
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
It is unknown if dasatinib passes into breast milk, but due to the potential for serious adverse reactions in a nursing infant, it is not recommended.
Actionable advice:
Do not breastfeed while taking dasatinib and for at least 2 weeks after the final dose.
Target id:
/class/h2-receptor-antagonists
Target name:
H2 Receptor Antagonists (H2 Blockers)
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
10
Hours after target:
2
Description:
H2 blockers (e.g., famotidine) reduce stomach acid, which can decrease the absorption of dasatinib. Spacing the doses apart can mitigate this interaction.
Actionable advice:
Take dasatinib at least 2 hours before or 10 hours after taking an H2 blocker.
Target id:
/class/antacids
Target name:
Antacids
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
Antacids (e.g., Tums, Maalox) neutralize stomach acid on contact, which can interfere with the dissolution and absorption of dasatinib if taken at the same time.
Actionable advice:
Separate administration of dasatinib and any antacids by at least 2 hours.
Target id:
/class/cyp3a4-moderate-inhibitors
Target name:
Moderate CYP3A4 Inhibitors
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Description:
Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil) slow the breakdown of dasatinib, leading to increased blood levels and a higher risk of side effects.
Actionable advice:
Use with caution and monitor for side effects; a dose reduction of dasatinib may be needed under medical guidance.
Target id:
/class/nsaids
Target name:
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Description:
NSAIDs (e.g., ibuprofen, naproxen) also have antiplatelet effects and can cause gastrointestinal irritation, increasing the risk of bleeding when taken with dasatinib.
Actionable advice:
Avoid long-term or high-dose NSAID use; use with caution for short periods if necessary and monitor for bleeding.
Target id:
/class/statins
Target name:
Statins (CYP3A4-metabolized)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Description:
Dasatinib can inhibit CYP3A4, potentially increasing the concentration of statins metabolized by this enzyme (e.g., simvastatin, atorvastatin, lovastatin), which elevates the risk of muscle-related side effects.
Actionable advice:
Use with caution and monitor for muscle pain; consider statins not metabolized by CYP3A4 like pravastatin or rosuvastatin.
Target id:
/condition/hepatic-impairment
Target name:
Hepatic Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Description:
Since dasatinib is extensively metabolized by the liver, impaired liver function can lead to increased drug levels and a higher risk of toxicity.
Actionable advice:
Use with caution and at a reduced dose in patients with moderate to severe hepatic impairment, under medical supervision.
Target id:
/intervention/quercetin
Target name:
Quercetin
Severity:
major
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Dasatinib and quercetin work together as a senolytic combination to clear senescent (aged) cells, which is the basis for its use in longevity protocols.
Actionable advice:
For senolytic purposes, take dasatinib and quercetin together at the same time as directed by a protocol.
Target id:
/dietary/meal
Target name:
Food/Meal
Severity:
minor
Interaction type:
requirement
Nature:
absolute
Description:
Dasatinib can be taken with or without food, but its absorption can be slightly altered by meals. Taking it in a consistent manner helps maintain stable drug levels.
Actionable advice:
Take dasatinib at the same time each day, either consistently with a meal or consistently on an empty stomach.